BioMimetix, a cutting-edge medtech company developing biomorphic programmable polymers for tissue reconstruction, has just announced the closure of its Series D round, raising an impressive €50 million from a mix of new international investors and returning ones.
The new backers include Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement, while returning investors include Cathay Health, Credit Mutuel Innovation, and last but not least, Sofinnova Partners.
TISSIUM just closed a major funding round that will help them take their nerve and hernia repair products to commercialisation. This comes as they reach important milestones like their first-in-human study of COAPTIUM Connect and other important regulatory activities. With the new financing, TISSIUM will be able to accelerate the development of their product pipeline and platform, bringing safe and effective solutions to the medical field.
TISSIUM is growing rapidly, leveraging its in-house production abilities and cutting-edge manufacturing facilities to rapidly expand internationally and explore new therapeutic areas. Strategic partnerships are also being established to accelerate the process and drive innovation.
Christophe Bancel, CEO of TISSIUM, is thrilled that the company’s Series D financing round has closed. This investment merges the ambitions of the organization with the possibility of bringing innovative tissue reconstruction products to the market.
With this funding injection, TISSIUM is on the fast-track to achieving its mission of improving the lives of patients everywhere. It’s time to put this money to good use and shape the future of tissue reconstruction.
TISSIUM, a pioneering MedTech company with a presence in both Paris and Boston, is revolutionizing tissue repair and reconstruction through its innovative biopolymer platform. Dedicated to tackling unmet patient needs, the company is leading the way in delivering cutting-edge solutions.
TISSIUM strives to revolutionize tissue reconstruction with its proprietary family of entirely biosynthetic, biomorphic, and programmable polymers. By utilizing these cutting-edge materials, the company offers seven groundbreaking products across three distinct verticals: sutureless nerve repair, hernia repair, and cardiovascular sealants.
Each product is tailored to meet the specific demands of surgical reconstruction, while delivery and activation devices enhance performance and ease-of-use. Together, they bring a new level of minimally-invasive, effective tissue repair.
TISSIUM has revolutionized drug delivery with its innovative technology rooted in cutting-edge research and intellectual property. Professors Robert Langer from MIT and Jeffrey M. Karp from Brigham and Women’s Hospital had the pioneering vision to co-found TISSIUM in 2013 – setting a new standard in drug delivery.